CHMP recommends Velsipity (etrasimod) for the treatment of ulcerative colitis – Pfizer
On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Velsipity, intended for the treatment of ulcerative colitis. The applicant for this medicinal product is Pfizer Europe. Velsipity will be available as a 2 mg film-coated tablet. The active substance of Velsipity […]
Recent Comments